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Introduction {#sec1}
============

Immunoglobulin A (IgA) is the antibody isotype that is produced in greatest quantities in the body. The majority of IgA molecules are secreted from the vast population of plasma cells (PCs) lining the entire gastrointestinal tract. These cells produce dimeric IgA in which two IgA monomers are covalently linked by the joining (J) chain. Dimeric IgA secreted in the lamina propria is transported across the epithelium via the polymeric immunoglobulin receptor and released into the gut lumen together with a fragment of the receptor known as the secretory component. These secretory IgA antibodies bind and regulate the intestinal microbiota and protect the epithelial barrier from pathogens ([@bib30]).

Differentiation of B cells into IgA-producing PCs may be the result of either T cell-dependent or T cell-independent activation ([@bib36], [@bib44]). Studies carried out in mice suggest that much of the IgA generated against gut commensal bacteria does not rely on classical T-B collaboration and that such antibodies often bind multiple bacterial strains with low affinity ([@bib29], [@bib4], [@bib41]). However, T cell-dependent IgA responses resulting in high-affinity, antigen-specific antibodies can be induced in mice by oral immunization ([@bib28]). Importantly, in humans, the majority of antibody-producing cells in the gut appear to be specific ([@bib3]). A prominent example of a human condition characterized by sizeable populations of antigen-specific gut PCs is celiac disease. This gluten-sensitive enteropathy is associated with marked changes in the tissue architecture of the upper small bowel and infiltration of immune cells, including large numbers of PCs, in the mucosa ([@bib45]). The immune reactions that lead to formation of the celiac disease lesion are orchestrated by CD4^+^ T cells, which recognize certain gluten peptides in the context of disease-associated HLA molecules. However, gluten peptides only become T cell antigens after modification by the enzyme transglutaminase 2 (TG2) through a process known as deamidation, whereby glutamine residues are converted to glutamic acid ([@bib34], [@bib49]). CD4^+^ T cells recognizing deamidated gluten can provide activation signals not only to cognate, gluten-specific B cells but also to self-reactive, TG2-specific B cells, which present gluten peptides on their surface upon internalization of TG2-gluten-B-cell receptor (BCR) complexes ([@bib19], [@bib46], [@bib45]). Hence, both gluten-specific and TG2-specific PCs can readily be detected in intestinal biopsy specimens obtained from celiac patients ([@bib31], [@bib12], [@bib47]). Interestingly, the latter specificity appears to dominate the response, and it was shown that, on average, 10% of IgA-producing cells in the lesion of untreated celiac disease patients are TG2 reactive ([@bib12]).

In addition to the IgA antibodies that are transported across epithelial barriers, the body also contains a pool of serum IgA. Unlike the IgA molecules that are secreted at mucosal surfaces, serum IgA is monomeric rather than dimeric and believed to be produced primarily by bone marrow PCs, although different production sites are possible ([@bib20]). Serum IgA and IgG antibodies against deamidated gluten and TG2 are also present in celiac disease, and because of their high disease specificity, such antibodies have become important diagnostic markers ([@bib24]). How these antibodies relate to gut PCs of the same specificities is not known, although it has been suggested that TG2-specific serum IgA ends up in the circulation as a result of spillover from the gut production ([@bib31], [@bib43]).

Analysis of the V-region repertoire in lymphocyte populations comprising hundreds or thousands of clones has become possible with the development of next-generation sequencing (NGS) methods. Further, combining sequencing data with analysis of isolated antibodies by liquid chromatography-tandem mass spectrometry (LC-MS/MS) has proven to be a powerful tool to establish connections between individual B cell clones and secreted antibodies ([@bib10], [@bib21]). Here, we apply the approach to investigate the relationship between gut PCs and antibodies in serum or biopsy secretions using TG2 or deamidated gluten peptide (DGP) to isolate specific cells and antibodies from celiac patient samples. In addition, LC-MS/MS can be applied independently to map preferences for individual V-gene segments in specific antibody pools ([@bib1]). Hence, by using purified celiac antibodies, we demonstrate that important characteristics of polyclonal antibody responses can be obtained without the need to interrogate PC populations.

Results {#sec2}
=======

Antibody Responses against Celiac Antigens Display Isotype-Dependent Differences {#sec2.1}
--------------------------------------------------------------------------------

In agreement with the well-established use of celiac antibodies in diagnostic tests, we found serum IgA and IgG antibodies targeting TG2 or DGP (peptide PLQPEQPFP) to be good markers for untreated celiac disease and readily detectable by ELISA ([Figure 1](#fig1){ref-type="fig"}A). For the IgA antibodies, it was evident that the reactivity against TG2 was higher than the reactivity against DGP, whereas this was not the case for the IgG antibodies. When comparing the IgA and IgG responses against each of the antigens, we found a much stronger correlation for the anti-DGP antibodies than for the anti-TG2 antibodies ([Figure 1](#fig1){ref-type="fig"}B). This difference might relate to the different nature of the antigens, as TG2 is a tissue-bound protein autoantigen, and DGP is a soluble peptide. Hence, DGP may distribute to different lymphoid structures in a concentration-dependent manner, whereas TG2 availability will be dictated by the expression levels in individual tissues.Figure 1Detection of Antigen-Specific Serum Antibodies and Gut PCs(A) Serum antibody reactivity against TG2 or DGP in patients with untreated celiac disease (UCD, n = 12) or control subjects (n = 12) as determined by ELISA. Sera were diluted 1:200 and added to biotinylated TG2 or biotinylated DGP (biotin-GSGSGS-PLQPEQPFP, harboring an immunodominant gliadin epitope) ([@bib39], [@bib47]) immobilized on streptavidin followed by detection of bound IgA or IgG using isotype-specific goat anti-human antibodies. The dynamic range of the assay was comparable for detection of the different antibodies. Open symbols indicate subjects from whom serum antibodies were purified for further characterization. The same symbols are used throughout this study.(B) Correlation between the levels of serum IgA and IgG against each of the two antigens in celiac disease patients (n = 20). Reactivity was measured by ELISA, and the signals for each antigen are given relative to the IgA signal obtained with a reference serum sample (UCD1283).(C) ELISPOT detection of total or antigen-specific antibody-secreting cells (ASCs) producing IgA or IgG in gut biopsy specimens obtained from celiac disease patients (n = 8). Cell suspensions were added to coated NeutrAvidin alone or NeutrAvidin associated with biotinylated TG2 or DGP as indicated. In the right panel, antigen specificity was not considered, and only the numbers of total IgA- or IgG-secreting cells were counted.(D) Correlations between the number of gut ASCs making antigen-specific IgA and the level of antigen-specific IgA in serum. EC~50~ values represent the serum dilution, which gives half-maximal response in ELISA. The right panel shows the ratio between TG2- and DGP-specific gut ASCs (x axis) and the corresponding ratio between serum antibody levels (y axis). Horizontal lines indicate means, and differences between groups were analyzed using repeated-measures one-way ANOVA. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001.

In agreement with previous observations, ELISPOT detection of antibody-secreting cells in duodenal biopsy specimens from celiac disease patients revealed that the number of TG2-specific IgA PCs was higher than the number of DGP-specific cells ([Figure 1](#fig1){ref-type="fig"}C) ([@bib47]). There was no correlation between the numbers of antigen-specific cells and the corresponding serum IgA levels ([Figure 1](#fig1){ref-type="fig"}D), as recently reported for the anti-TG2 response ([@bib13]). However, the ratio between the numbers of TG2- and DGP-specific cells reflected the ratio between the levels of the IgA antibodies in serum. That is, for each patient, the observed dominance of anti-TG2 over anti-DGP IgA was equal in serum and gut samples. These findings suggest that the serum IgA responses are tightly connected to PC generation in the gut, although the gut PCs might not be the direct source of serum antibodies. As expected, the total number of IgG-secreting cells in the gut was much lower than the number of IgA-secreting cells ([@bib5]), and only a few cases of antigen-specific IgG cells could be detected ([Figure 1](#fig1){ref-type="fig"}C). Thus, it appears that the cells secreting celiac IgG antibodies are not primarily generated in the gut.

Serum Anti-TG2 Antibodies Primarily Target Epitopes Known from Gut PCs {#sec2.2}
----------------------------------------------------------------------

The antibody response against TG2 was previously characterized by generation of monoclonal antibodies (mAbs) from TG2-specific gut PCs of celiac disease patients ([@bib12]). The majority of these mAbs could be placed into three main epitope groups (epitopes 1--3), which reflected antibody *IGHV* gene segment usage ([@bib17]). Notably, epitope 1, which is recognized by antibodies using *IGHV5--51*, was targeted by 30 out of 57 mAbs. Epitope mapping studies have revealed that the epitopes are partly overlapping and located in the N-terminal part of the TG2 protein ([Figure S2](#mmc1){ref-type="supplementary-material"}A) ([@bib18], [@bib8]). In order to test whether the N-terminal domain of TG2 is also important for binding of serum antibodies in celiac disease, we purified antibodies from patient serum samples ([Figure S1](#mmc1){ref-type="supplementary-material"}A--S1C) and assessed the IgA reactivity against TG2 variants with either the N-terminal domain replaced by the N-terminal domain of TG3 or the two C-terminal domains missing ([Figure 2](#fig2){ref-type="fig"}A). Replacement of the N-terminal domain reduced the reactivity of patient serum IgA dramatically, whereas the two C-terminal domains could be removed without great loss of reactivity. Thus, as previously found for anti-TG2 mAbs generated from gut PCs, IgA antibodies in serum primarily target epitopes in the N-terminal part of TG2.Figure 2Epitope Targeting by Anti-TG2 Serum IgA(A) Reactivity of total IgA purified from sera of celiac disease patients (n = 5) against different transglutaminase variants assessed by ELISA. In the TG3/TG2 protein, the N-terminal domain of TG2 was replaced with the N-terminal domain of TG3, whereas TG2 1--465 indicates a truncated TG2 variant lacking the two C-terminal domains. Reactivity levels are given relative to the signals obtained with wild-type (WT) TG2 and were compared using a paired t test. ^∗^p \< 0.05.(B) Ability of individual mAbs targeting epitope 1, 2, or 3 (e1--3) to outcompete binding of purified total serum IgA to TG2. Supernatants from cultured gut biopsy specimens obtained from celiac disease patients (n = 6) were included for comparison.(C) Ability of the indicated mAbs to outcompete TG2-binding of IgA in whole sera of adult patients (n = 23) or children (n = 23) in whom celiac disease recently developed. Notably, the epitope 1 mAb shows reduced competitive capacity when using whole sera instead of purified serum IgA (compare B and C). Horizontal lines indicate means.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

To further assess the overlap between epitopes targeted by serum antibodies and mAbs generated from gut PCs, we produced three typical mAbs targeting epitope 1, 2, or 3 by recombinant expression in 293 cells and assessed their ability to outcompete purified serum IgA in binding to TG2 ([Figure 2](#fig2){ref-type="fig"}B). Importantly, the mAbs showed a similar degree of competition between purified serum IgA and IgA secreted from PCs in gut biopsy specimens obtained from celiac disease patients, indicating that the distribution of reactivity among individual TG2 epitopes is the same for serum IgA and gut PCs ([Figure 2](#fig2){ref-type="fig"}B).

Whole serum samples rather than purified antibodies are typically used for studying TG2 reactivity. However, the use of whole serum samples results in underestimation of the contribution of epitope 1 specificity because of the serum content of fibronectin, which binds to TG2 with high affinity and competes with epitope-1-targeting antibodies for binding ([Figures S1A--S2](#mmc1){ref-type="supplementary-material"}C) ([@bib17], [@bib6]). Although the epitope 1 reactivity was thus partly masked, we used whole serum samples to compare epitope targeting between adult celiac disease patients, who are likely to have had an ongoing immune response for extended periods of time, and children with recently developed disease. The degree of competition between anti-TG2 mAbs and serum IgA was comparable in the two patient groups ([Figure 2](#fig2){ref-type="fig"}C). Hence, the same main epitopes are targeted very early in disease development and at later stages, in agreement with previous observations ([@bib40]).

Serum Antibodies against Celiac Antigens Use the Same V-Gene Segments as Gut PCs {#sec2.3}
--------------------------------------------------------------------------------

To further compare antigen-specific serum antibodies with the gut immune response, we purified the TG2-reactive fraction from either serum IgA or IgA secreted from gut biopsy PCs and analyzed TG2-binding and non-TG2-binding trypsinized fractions by LC-MS/MS. Peptides derived from antibody V-gene segments were identified using a database containing germline immunoglobulin sequences supplemented with peptides identified by de novo sequencing ([Figure S3](#mmc1){ref-type="supplementary-material"}). De-novo-sequenced peptides were included in the database if their amino acid sequence contained one mismatch compared to any germline sequence. By allowing identification of such non-germline sequences, we were able to account for somatic hypermutation, leading to a substantial increase in the number of peptides that could be assigned to each V-gene segment ([Table S1](#mmc1){ref-type="supplementary-material"}). Relative abundances of individual V-gene segments were then determined by summing up the peak intensities from the assigned peptides, allowing comparison of TG2-specific and non-TG2-specific antibodies. Ten V-gene segments were overrepresented in the TG2-binding IgA fraction in all five patients analyzed, and the same preferences were observed in serum and in biopsy secretions ([Figure 3](#fig3){ref-type="fig"}A; [Table S2](#mmc1){ref-type="supplementary-material"}). Importantly, heavy and light chain V-gene segments found to be overrepresented among TG2-binding antibodies were in agreement with previous findings based on sequencing of the antibody genes in TG2-specific gut PCs ([@bib12], [@bib42], [@bib38]), and the distribution of LC-MS intensity between different *IGHV* families reflected the distribution of sequences obtained from gut PCs of the same patient ([Figure 3](#fig3){ref-type="fig"}B). Hence, antigen-dependent V-gene preferences can be mapped efficiently by LC-MS/MS. *IGHV5-51* was the only *IGHV* segment that was consistently overrepresented among TG2-binding serum antibodies, reflecting a generally strong contribution of antibodies targeting epitope 1 to the anti-TG2 pool in celiac disease. To further confirm the connection between antigen-specific IgA in serum and gut PCs, we repeated the analysis using purified anti-DGP serum IgA. Also in this case, we identified an overrepresentation of V-gene segments previously found to be used by DGP-specific PCs, with the exception of *IGHV3-23*, which was not identified because of the lack of unique peptides mapping to this V-gene segment ([Table S2](#mmc1){ref-type="supplementary-material"}) ([@bib47]). Collectively, these data show that both anti-TG2 and anti-DGP serum IgA antibodies are dominated by the same V-gene segments, which are preferentially used by the corresponding gut PC populations.Figure 3Bias in V-Gene Segments Used by Anti-TG2 IgA Antibodies(A) Volcano plot showing differences in the use of V-gene segments between affinity-purified anti-TG2 IgA and non-TG2-specific IgA (flow-through fraction) obtained from serum or gut biopsies of a representative celiac disease patient (UCD1317). Functional V-gene segments were identified based on matching of MS/MS spectra to amino acid sequences obtained from <http://www.imgt.org>, resulting in detection of unique peptides for 80% of the database V-gene segments. The amounts of individual V-gene segments in each sample were quantified using MaxQuant software ([@bib11]). V-gene segments significantly more abundant in the TG2-specific fraction are indicated with blue symbols, whereas V-gene segments of lower abundance are shown in red (p \< 0.05). V-gene segments overrepresented among TG2-specific serum IgA in all five patients analyzed are indicated with their names, and names shown in bold indicate V-gene segments, which were previously found to be used by TG2-specific gut PCs ([@bib12], [@bib42], [@bib38]).(B) Distribution of antibodies and PCs among different *IGHV* families in UCD1317. The distribution of TG2-specific and non-TG2-specific gut PCs is based on the numbers of unique sequences obtained by NGS, whereas the distribution of affinity-purified anti-TG2 or flow-through IgA isolated from serum or gut biopsy specimens is based on *IGHV* peptide LC-MS intensities obtained as intensity-based absolute quantification (iBAQ) values in MaxQuant. Error bars represent SD based on triplicate LC-MS/MS runs.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Sharing of CDR-H3 Sequences between Serum Antibodies and Gut PCs {#sec2.4}
----------------------------------------------------------------

In order to test whether antigen-specific serum antibodies are clonally related to gut PCs, we obtained CDR-H3 sequences from sorted TG2- or DGP-specific gut PCs and looked for matching amino acid sequences in affinity-purified antibody fractions from the same celiac disease patients using LC-MS/MS ([Table 1](#tbl1){ref-type="table"}; [Figure S3](#mmc1){ref-type="supplementary-material"}). Antibody-derived peptide sequences matching CDR-H3 sequences of individual TG2-specific PCs could be detected both in serum IgA and in IgA secreted from gut biopsy PCs. Not all PC clonotypes were detected at the antibody level, but they were essentially the same sequences observed in serum and in biopsy secretions ([Figure 4](#fig4){ref-type="fig"}A; [Table S3](#mmc2){ref-type="supplementary-material"}). Typically, most of the intensity was derived from a few prevalent clonotypes that often were represented by more than one peptide ([Tables 1](#tbl1){ref-type="table"} and [S3](#mmc2){ref-type="supplementary-material"}). Surprisingly, serum IgA and biopsy-derived IgA contained comparable levels of anti-TG2 CDR-H3 peptides ([Figure 4](#fig4){ref-type="fig"}B), suggesting that all gut PCs are also represented in the serum IgA pool. Further, our data imply that the entire anti-TG2 repertoire is contained within the small amount of gut tissue that was collected. In support of this notion, it was previously shown that individual biopsy specimens share a high number of clonotypes, indicating that relatively few clonally expanded founder cells make up the anti-TG2 repertoire in the gut ([@bib13]). Anti-TG2 CDR-H3 peptides were clearly enriched in the TG2-binding fraction compared to the flow-through fraction collected during anti-TG2 affinity purification, confirming that the identified peptides indeed reflect TG2 specificity ([Figure 4](#fig4){ref-type="fig"}B). Likewise, enrichment of anti-DGP CDR-H3 peptides could be observed after affinity purification of anti-DGP serum IgA, although the low concentration of DGP-specific IgA in serum resulted in few detected peptides ([Figure 4](#fig4){ref-type="fig"}C; [Table S4](#mmc3){ref-type="supplementary-material"}).Figure 4Sharing of CDR-H3 Sequences between Purified IgA Fractions and Gut PCs(A) Matching between peptide sequences obtained from affinity-purified anti-TG2 IgA and CDR-H3 sequences of TG2-specific IgA gut PCs. Antibodies were isolated from serum or gut biopsy specimens, and peptides containing all or part of a CDR-H3 region were identified by LC-MS/MS based on matching to a database of CDR-H3 sequences obtained from TG2-specific gut PCs of the same celiac disease patient (UCD1317) by NGS. Sequences from PCs were grouped into clonotypes, which were ranked from 1 to 121 according to decreasing numbers of sequenced transcripts (i.e., clonotype 1 was associated with the highest number of immunoglobulin mRNA molecules). Bars show the summed LC-MS intensities of peptides matching individual clonotypes as a percentage of the total anti-TG2 CDR-H3 peptide intensity of each sample. Hence, each bar represents detection of a particular clonotype at the antibody level. The data are representative of four analyzed patients (summarized in [Table 1](#tbl1){ref-type="table"}).(B) Quantification of the amount of antibodies containing CDR-H3 regions matching sequences of TG2-specific gut PCs in affinity-purified anti-TG2 antibodies or the TG2 flow-through (FT) fraction of celiac disease patient samples. TG2-binding and non-TG2-binding fractions were isolated from purified total IgA of sera or gut biopsy specimens. The normalized level of anti-TG2 CDR-H3 regions in each sample (the anti-TG2 CDR-H3 index) was determined by dividing the number of identified peptides containing TG2-specific CDR-H3 sequences with the number of all CDR-H3-containing peptides that could be identified by de novo peptide sequencing.(C) Detection of peptides matching CDR-H3 sequences obtained from DGP-specific gut PCs in anti-DGP or DGP FT IgA isolated from purified total serum IgA of two celiac disease patients. Because of the low concentration of DGP-specific IgA, CDR-H3 indices could not be calculated, as was done for the TG2-specific antibodies. Horizontal lines indicate means.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S3](#mmc2){ref-type="supplementary-material"} and [S4](#mmc3){ref-type="supplementary-material"}.Table 1Detection of CDR-H3 Sequences from Antigen-Specific Gut PCs in Affinity-Purified Serum or Gut IgA by LC-MS/MSNGS: Gut PCsLC-MS/MS: Serum or Gut IgA[a](#tblfn1){ref-type="table-fn"}No. of PCsNo. of SequencesUnique CDR-H3 SequencesClonotypes[b](#tblfn2){ref-type="table-fn"}CDR-H3 Peptides DetectedClonotypesTop Clonotype Intensity (%)[c](#tblfn3){ref-type="table-fn"}Anti-TG2UCD12791,1001,21746636427/2026/2015/14UCD12832,5002,561573340835318UCD12872,5007,1371,324741997543UCD13179701,30525312149/6035/3654/38Anti-DGPUCD12831,3002741401347473UCD12875507531641325367[^2][^3][^4][^5][^6]

Serum IgG Exhibits Weaker Clonal Relatedness to Gut PCs than Serum IgA {#sec2.5}
----------------------------------------------------------------------

Unlike purification of total serum IgA, purification of total serum IgG was associated with accumulation of low-affinity TG2-binding antibodies, which did not bind the antigen in whole serum and were not related to celiac disease ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). Hence, the TG2-specific IgG fraction could not be isolated and analyzed after initial purification of total IgG in a way similar to that described above for the IgA antibodies. However, when TG2-binding antibodies were isolated from whole serum without initial separation into total IgA and IgG preparations, we were able to detect IgG-derived anti-TG2 CDR-H3 peptides in the fraction eluted from TG2 based on the sequence of constant-region amino acids following the CDR-H3 region ([Figure 5](#fig5){ref-type="fig"}A; [Table S5](#mmc4){ref-type="supplementary-material"}). Thus, anti-TG2 CDR-H3 sequences obtained from gut PCs are represented among both serum IgA and serum IgG and are detectable after purification of TG2-binding molecules from whole serum samples. However, sequences shared with gut PCs seemed to be less frequent in anti-TG2 IgG than in anti-TG2 IgA ([Figure 5](#fig5){ref-type="fig"}B), and most of the detected anti-TG2 CDR-H3 peptides were different for the two antibody classes ([Figure 5](#fig5){ref-type="fig"}C). Thus, there exist serum IgA and IgG antibodies that are clonally related to gut PCs, but the connection is stronger for IgA than for IgG.Figure 5Detection of PC CDR-H3 Sequences in Anti-TG2 IgA and IgG Isolated from Whole Sera(A) Quantification of the amount of antibodies with CDR-H3 regions matching sequences of TG2-specific gut PCs among affinity-purified anti-TG2 or TG2 flow-through (FT) IgG obtained from whole sera of three celiac disease patients. The anti-TG2 CDR-H3 levels are determined as CDR-H3 indices as shown in [Figure 4](#fig4){ref-type="fig"}B. Horizontal lines indicate means.(B) Comparison of the level of anti-TG2 CDR-H3 peptides derived from IgA or IgG after isolation of TG2-binding antibodies from whole serum samples. Connecting lines indicate detection of IgA- and IgG-derived CDR-H3 peptides in the same sample. The anti-TG2 CDR-H3 levels were compared using a paired t test. ^∗∗^p \< 0.01.(C) Venn diagrams showing overlap between anti-TG2 CDR-H3 peptides detected in affinity-purified anti-TG2 IgA or IgG obtained from whole serum or from purified total serum IgA of three celiac disease patients. Numbers indicate identified peptides containing CDR-H3 regions matching sequences obtained from TG2-specific gut PCs of the same patient. Area-proportional ellipses were generated using euler*APE* ([@bib33]).See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc4){ref-type="supplementary-material"}.

Serum and Gut Anti-TG2 IgA Display Different Molecular Compositions {#sec2.6}
-------------------------------------------------------------------

To get an indication of the cellular origin of antigen-specific serum IgA in celiac disease, we assessed the distribution between monomeric and dimeric forms in TG2-specific IgA purified from celiac patient serum or gut biopsy secretions. The TG2-specific IgA fractions appeared similar to the total IgA preparations, with antibodies purified from serum being mostly monomeric and antibodies purified from biopsy specimens being dimeric ([Figure 6](#fig6){ref-type="fig"}A).Figure 6Composition of IgA Fractions Obtained from Sera or Gut Biopsy Specimens(A) Western blot showing detection of monomeric and dimeric forms of purified total or TG2-specific IgA obtained from serum or gut biopsies of a celiac disease patient (UCD1317). The appearance of anti-TG2 serum IgA is representative of five analyzed patients.(B) LC-MS/MS quantification of the amount of J chain and IgA2 subclass in the TG2-specific or TG2 flow-through (FT) fractions of total IgA in sera or gut biopsy specimens obtained from two celiac disease patients. Quantification is based on iBAQ values obtained with MaxQuant and is given relative to the summed iBAQ values of the IgA1 and IgA2 constant regions in each sample. The method overestimates the amount of J chain somewhat, as a dimeric IgA molecule consists of four IgA heavy chains and one J chain, giving a maximum J chain/IgA molar ratio of 0.25. Error bars represent SD based on duplicate (UCD1279) or triplicate (UCD1317) LC-MS/MS runs.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

The relative abundances of individual proteins in a sample can be approximated from the peptide intensities of extracted-ion chromatograms ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}A). Thus, to obtain further insight into the molecular composition of different IgA fractions, we quantified the levels of J chain and the distribution of IgA molecules between the IgA1 and IgA2 subclasses ([Figure 6](#fig6){ref-type="fig"}B). In agreement with the observed distributions between monomers and dimers, gut biopsy IgA contained higher levels of J chain than serum IgA. However, TG2-specific serum IgA seemed to be associated with more J chain than the non-TG2-specific serum fraction. As expected, both serum IgA and IgA secreted from duodenal biopsy specimens consisted mostly of IgA1 ([Figure 6](#fig6){ref-type="fig"}B) ([@bib5]). Both in serum and in biopsy secretions, the TG2-specific fraction contained even lower levels of IgA2 than the non-TG2-specific fraction, but while IgA2 still made up an estimated 5%--10% of TG2-specific IgA in the gut, this subclass was virtually absent in the TG2-specific serum IgA fraction. Collectively, these data demonstrate that the TG2-specific IgA antibodies present in serum and gut biopsy secretions have different molecular compositions, suggesting that the majority of anti-TG2 serum antibodies are not produced by gut PCs, although some J-chain-containing IgA dimers generated in the gut might end up in the circulation, either by escaping transport across the epithelium or via retrotransport from the gut lumen mediated by binding of secretory IgA to CD71 on the apical surface of epithelial cells ([@bib22]). In support of the latter mechanism, we did detect low amounts of the polymeric immunoglobulin receptor among serum antibodies eluted from TG2 by LC-MS/MS ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Notably, the IgA response against TG2 is skewed toward production of IgA1, and the PCs responsible for secretion of serum anti-TG2 IgA seem to be recruited almost exclusively from IgA1-expressing cells. Likewise, we observed a biased distribution of anti-TG2 serum IgG in favor of the IgG1 subclass ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

Discussion {#sec3}
==========

The relationship between mucosal and systemic immune responses is not well understood, and the origin of circulating antibodies against gut antigens has not previously been investigated thoroughly. In this study, we have characterized the antibody response against two antigens, TG2 and DGP, in celiac disease patients. Both responses are dependent on a gluten-containing diet and are associated with accumulation of antigen-specific PCs in the gut lesion. Strikingly, serum IgA antibodies targeted the same epitopes and used the same preferred V-gene segments as the gut PCs. Moreover, detection of antigen-specific CDR-H3 regions showed that serum antibodies and gut PCs are clonally related. Analogous to what has recently been observed for vaccine-elicited anti-flu antibodies ([@bib23]) and anti-desmoglein autoantibodies ([@bib9]), we found that relatively few clonotypes contributed most of the serum LC-MS intensity that could be ascribed to anti-TG2 CDR-H3 peptides. These clonotypes also represented some of the most abundant gut PCs, as judged by the number of sequenced transcripts, thus underscoring the tight connection between serum and gut IgA.

Despite the strong clonal relatedness between serum antibodies and gut PCs, we found anti-TG2 serum IgA to be mostly monomeric, whereas anti-TG2 antibodies secreted by gut PCs were J-chain-associated dimers and contained a larger fraction of the IgA2 subclass. Similar molecular differences have also been described for gluten-specific serum and gut IgA in celiac disease ([@bib50]). Together with the lack of correlation between gut PC numbers and serum antibody levels, these findings suggest that gut PCs are not the direct source of the specific serum IgA antibodies.

Independent regulation of IgA responses in gut and serum has previously been observed in CD28-deficient mice ([@bib14]). Our data are in agreement with this concept but at the same time strongly suggest that serum antibodies and gut PCs originate from the same B cell clones. In line with this model, IgA-expressing cells derived from mucosal immune responses are present in human blood and in bone marrow during steady-state conditions ([@bib32]). Further, it was recently shown that antigen-specific, clonally related PCs are present in the bone marrow and gut after oral immunization of mice ([@bib2], [@bib26]). Hence, together with previous studies, the data presented here contend that B cells activated in the gut immune system give rise to PCs that reside in the lamina propria and produce dimeric IgA for transport across the epithelium as well as an equivalent population of PCs that migrate to the bone marrow and secrete monomeric IgA into the circulation.

We observed that CDR-H3 sequences obtained from TG2-specific gut PCs were represented both in the IgA fraction and in the IgG fraction of TG2-binding serum antibodies. In agreement with this finding, sharing of V-region sequences between TG2-specific gut PCs and IgG memory cells was previously demonstrated in celiac disease ([@bib42]). Additionally, clonally related IgA and IgG PCs could be detected in orally immunized mice ([@bib2]). Thus, single B cells can give rise to both IgA- and IgG-expressing cells. However, compared to IgA antibodies, anti-TG2 IgG displayed a lower frequency of CDR-H3 sequences that were shared with gut PCs. One explanation for this observation could be that IgA- and IgG-expressing cells, despite being clonally related, acquire different V-region mutations and therefore tend to differ in their CDR-H3 sequences, as recently shown for B cell clonotypes comprising cells of different immunoglobulin classes ([@bib16]). Alternatively, many of the TG2-specific IgG PCs are generated from a separate population of B cell clones, possibly at other anatomical locations. Such a distinction might explain why anti-TG2 IgG is generally a poorer diagnostic marker than anti-TG2 IgA ([@bib24]).

Immune reactions involving gluten might occur at sites distant from the gut, as exemplified by the conditions dermatitis herpetiformis and gluten ataxia, which can be considered extraintestinal manifestations of celiac disease affecting the skin and brain, respectively. Relevant to these clinical observations, gluten-derived peptides can be detected in urine following gluten consumption, demonstrating that antigenic peptides are systemically distributed ([@bib35]). The observed tight connection between serum levels of anti-DGP IgA and IgG might reflect the presence of gluten peptides both in the gut and in the circulation, as mucosal immune responses primarily give rise to IgA production while systemic responses are dominated by IgG ([@bib32]). Thus, the IgA response could be initiated in Peyer's patches or mesenteric lymph nodes, whereas the spleen might also contribute to IgG induction. The anti-TG2 response, on the other hand, did not show the same strong correlation between IgA and IgG levels. Although this response is also dependent on availability of gluten peptides, it should also reflect the TG2 expression and activity levels, which may vary between different tissues. Thus, if anti-TG2 IgA and IgG mainly originate from different B cell populations at different anatomical sites, the local levels of available, active TG2 enzyme might control the relative contribution of the two isotypes to the serum antibody pool.

In conclusion, by using a combination of NGS and LC-MS/MS, we have shown that there is a close relationship between PCs in the gut and serum IgA antibodies against two different antigens in celiac disease patients. Although the gut PCs do not seem to produce the antibodies present in serum, a high level of shared CDR-H3 sequences implies that serum IgA and gut PCs are clonally related. Gut PC CDR-H3 sequences could also be detected in serum IgG, indicating that B cell clones activated in the mucosal immune system contribute to the serum IgG pool. In addition, we demonstrate the use of LC-MS/MS alone to obtain characteristics of affinity-purified antibodies, including V-gene preferences and subclass distributions. This analysis can be useful for assessing the composition of antibody responses against various antigens and requires only a serum sample.

Experimental Procedures {#sec4}
=======================

Human Samples {#sec4.1}
-------------

Blood and/or duodenal biopsy specimens were collected from 32 adult celiac disease patients and 12 control subjects who had given their informed consent. Ethical approval was given by the Regional Ethics Committee of South-Eastern Norway (project 2010/2472), and the diagnosis of celiac disease was given according to the recent guidelines of the British Society of Gastroenterology ([@bib27]). In addition, 23 serum samples of young children (median age 2.8 years, range 1.9--5 years) with newly diagnosed celiac disease were included from the Hungarian participants in the PreventCD project (<http://www.preventceliacdisease.com>), a prospective FP6 European multicenter study following at-risk infants from celiac families after randomized gluten introduction at 4 or 6 months of age. Blood was collected upon informed consent from the parents 7 times until 3 years of age and then annually. Ethical approval was given by the ethics committees of all participating centers, including that of Heim Pál Children's Hospital (Budapest, Hungary). Unless otherwise stated, the analyzed samples were from adult celiac disease patients. Biopsy specimens (6--12 from each patient) were disrupted by incubation with 1 mg/mL collagenase (Sigma) in 2% (v/v) fetal calf serum (FCS)/PBS under constant rotation for 1 hr at 37°C. The digested sample was homogenized with a syringe and filtered through a 40-μm cell strainer. The obtained single-cell suspension was either used directly or cultured for 2--4 weeks in 10% (v/v) FCS/RPMI-1640 together with human intestinal fibroblasts as previously described ([@bib47]) prior to staining and fluorescence-activated cell sorting (FACS) of PCs. Supernatants from cultured biopsy specimens were collected for isolation of secreted antibodies.

Recombinant Proteins {#sec4.2}
--------------------

Recombinant human TG2 (Phadia) and TG3 (Zedira) produced in insect cells were used to assess antibody binding to the wild-type proteins by direct coating in ELISA as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Proteins produced in *Escherichia coli* were used for comparison of wild-type TG2 and variants without the two C-terminal domains (residues 1--465) ([@bib17]) or with the N-terminal domain replaced by the N-terminal domain of TG3 (residues 1--136 from TG3 and residues 141--687 from TG2) ([@bib7]). For attachment to streptavidin or NeutrAvidin, we used TG2 produced in *E. coli* with an N-terminal BirA biotinylation sequence ([@bib15]). Site-specific biotinylation was carried out with the BirA biotin-protein ligase (Avidity) according to the instructions provided by the manufacturer. Anti-TG2 mAbs targeting different epitopes were expressed as human IgG1 molecules in HEK293-F cells and purified on protein G (GE Healthcare) as previously described ([@bib8]). The Jo-1 antigen was obtained from Phadia.

LC-MS/MS Sample Preparation {#sec4.3}
---------------------------

Antigen-specific antibodies were purified from serum or supernatants of cultured gut biopsies as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. The eluate and flow-through fractions were dried under vacuum followed by resuspension in 50 μL 50 mM NH~4~HCO~3~, 8 M urea. The antibodies were reduced with 10 mM DTT for 1 hr at 60°C followed by alkylation with 30 mM iodoacetamide for 1 hr at room temperature. The samples were then diluted with 150 μL 50 mM NH~4~HCO~3~ before overnight digestion with Sequencing Grade Trypsin (Promega) at 37°C, using a trypsin/antibody ratio of 1:50 (w/w). The reaction was quenched by addition of trifluoracetic acid to a final concentration of 1% (v/v). Peptides were cleaned prior to LC injection by the STAGE-TIP method ([@bib37]) using a C18 resin disk (3M Empore). Sample analyses were based on duplicate or triplicate runs using an Easy nLC1000 nano-LC system connected to a quadrupole Orbitrap (Q Exactive) mass spectrometer (ThermoElectron) equipped with a nanoelectrospray ion source (EasySpray/Thermo) as detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Database Generation {#sec4.4}
-------------------

In order to increase identification coverage of antibody V-gene segments, we used a de novo approach to include mutations in the reference germline database, which contained amino acid sequences of all human V-gene segments obtained from the International ImMunoGeneTics Information System (IMGT) database ([@bib25]). By using the germline database for proper sequence alignment, peptides carrying single amino acid substitutions were identified and added to the database as detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Identification of CDR-H3 Peptides {#sec4.5}
---------------------------------

For identification of CDR-H3 sequences obtained by NGS at the protein level, a database of complete tryptic peptides containing CDR-H3 sequences was built for each patient by adding the last six J-segment amino acids and the beginning of the constant region (ASTK for IgG and ASPTSPK for IgA) to the antibody sequences. Matching peptides from antigen-specific and non-specific antibody fractions were then identified by LC-MS/MS. In addition to CDR-H3 amino acids, all analyzed CDR-H3 peptides contained the conserved J-segment and constant-region sequences, and some peptides might therefore have been too long for detection. However, many CDR-H3 regions contained internal tryptic cleavage sites, resulting in shorter peptides harboring only part of the CDR-H3 region (see [Tables S3](#mmc2){ref-type="supplementary-material"}, [S4](#mmc3){ref-type="supplementary-material"}, and [S5](#mmc4){ref-type="supplementary-material"} for the complete list of identified CDR-H3 peptides). In order to normalize the number of database CDR-H3 peptides that could be detected in a sample, we used de novo sequencing to identify peptides harboring CDR-H3 regions of any specificity, characterized as amino acid sequences ending in ASTK (IgG) or ASPTSPK (IgA).

Sequencing of Antigen-Specific PCs {#sec4.6}
----------------------------------

Antigen-specific IgA PCs in gut biopsy specimens were FACS sorted and their heavy chain V regions sequenced using Illumina MiSeq as detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. *IGHV*, *IGHJ*, and CDR-H3 were assigned using IMGT, and clonal relatedness between sequences was established based on matching *IGHV* and *IGHJ* gene segments, identical CDR-H3 length, and ≥85% sequence identity throughout the CDR-H3 region ([@bib48]).

ELISPOT {#sec4.7}
-------

MultiScreen 96-well filter plates (Millipore) were coated with 5 μg/mL NeutrAvidin (Thermo) or goat anti-human Ig (Southern Biotech) in PBS. The wells were washed with PBS and blocked with 1% (w/v) BSA/PBS before biotinylated TG2 (5 μg/mL) or biotinylated DGP (100 nM) was added to coated NeutrAvidin. After washing with PBS, various dilutions of gut biopsy single-cell suspensions were added to the wells in 10% (v/v) FCS/RPMI and incubated overnight at 37°C in a CO~2~ incubator. The cell suspensions were discarded, and the wells were washed with PBS and PBS containing 0.1% (v/v) Tween 20 (PBST). Bound IgA or IgG was detected by incubation with alkaline-phosphatase-conjugated goat anti-human IgA or goat anti-human IgG in 1% (w/v) BSA/PBST followed by washing and addition of BCIP/NBT substrate (Bio-Rad). Spots were counted using an ImmunoSpot analyzer (Cellular Technology Limited).

Western Blotting {#sec4.8}
----------------

Purified TG2-specific or total IgA samples were boiled in non-reducing SDS-PAGE sample buffer and separated on a 4%--20% TGX gel (Bio-Rad). Proteins were blotted onto nitrocellulose, and the membrane was blocked in 2% (w/v) skim milk/PBS. IgA was detected using rabbit anti-human IgA (Dako) followed by horseradish-peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech).

Statistics {#sec4.9}
----------

Data are presented as mean ± SD and analyzed using GraphPad Prism software, unless otherwise stated. Differences between groups were analyzed using one-way ANOVA or Student's t test, and scatterplots were analyzed by Pearson correlation analysis. A p value of \<0.05 was considered significant.
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The accession numbers for the raw mass spectrometry data and antibody sequences used for creating search databases are MassIVE: MSV000081328 (<http://massive.ucsd.edu>) and ProteomeXchange: [PXD007047](pride:PXD007047){#intref0020}.
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[^1]: Lead Contact

[^2]: LC-MS/MS, liquid chromatography-tandem mass spectrometry; NGS, next-generation sequencing; PCs, plasma cells.

[^3]: See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S3](#mmc2){ref-type="supplementary-material"} and [S4](#mmc3){ref-type="supplementary-material"}.

[^4]: Numbers reflect CDR-H3 peptides identified in serum IgA. When two numbers are given, they indicate peptides identified in serum/biopsy supernatant.

[^5]: Sequences assigned to the same clonotype use the same *IGHV* and *IGHJ* gene segments and have ≥85% sequence identity in the CDR-H3 region ([@bib48]).

[^6]: The LC-MS intensity of the highest-intensity clonotype is given relative to the total LC-MS intensity of all identified CDR-H3 peptides in the sample.
